| Lai, Yongrong |
NCT04009525: Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study |
|
|
| Completed | 4 | 823 | RoW | Busulfan, Bu, Cyclophosphamide, Cy, Fludarabine, Flu, Thymoglobulin, ATG, cyclosporine A, CsA, Mycophenolate mofetil, MMF, Tacrolimus, FK506, Methotrexate, MTX | First Affiliated Hospital of Guangxi Medical University, Peking University People's Hospital, Ruijin Hospital, The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, LiuZhou People's Hospital, The First People's Hospital of Yunnan, Liuzhou Workers Hospital, Xinqiao Hospital of Chongqing, Affiliated Hospital of Youjiang University of Ethnic Medicine, Hainan People's Hospital, Maoming People's Hospital, Red Cross Hospital of Yulin City, Guilin Medical College, Wuzhou People's Hospital, Guangxi Autonomous Region People's Hospital, The 920th Hospital of Joint Logistics Support Force of People's Liberation Army | Thalassemia Major | 07/23 | 10/23 | | |
NCT06302491: A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia |
|
|
| Recruiting | 2 | 64 | RoW | AND017 capsules, AND017 Placebo | Kind Pharmaceuticals LLC | β -Thalassemia | 12/25 | 07/26 | | |
NCT06465550: A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major |
|
|
| Recruiting | 1 | 9 | RoW | BD211 | Shanghai BDgene Co., Ltd. | β-thalassemia | 12/26 | 12/26 | | |
| Enrolling by invitation | 1 | 10 | RoW | CS-101 | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Beta-Thalassemia | 12/25 | 01/26 | | |
NCT06291961: A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major |
|
|
| Recruiting | 1 | 8 | RoW | CS-101 injection | CorrectSequence Therapeutics Co., Ltd | Beta-Thalassemia Major | 05/25 | 07/25 | | |
NCT06655662: Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients. |
|
|
| Recruiting | 1 | 8 | RoW | β-globin restored autologous hematopoietic stem cells | Shenzhen Hemogen | Β-thalassemia | 12/25 | 12/26 | | |
| Recruiting | 1 | 5 | RoW | CS-206 | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Sickle Cell Disease | 12/26 | 06/27 | | |
NCT06772766: A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia |
|
|
| Recruiting | 1 | 40 | RoW | 9MW3011, 9MW3011 placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Beta-Thalassemia | 10/26 | 10/26 | | |
NCT06024876: A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia |
|
|
| Active, not recruiting | 1 | 5 | RoW | CS-101 | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Beta-Thalassemia | 12/24 | 06/25 | | |
NCT05577312: Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia |
|
|
| Enrolling by invitation | 1 | 9 | RoW | BRL-101, BRL-101 autologous hematopoietic stem and progenitor cells injection | Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University | Beta-Thalassemia | 08/25 | 09/26 | | |
NCT05762510: A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT] |
|
|
| Recruiting | 1 | 5 | RoW | GMCN-508B (LentiRed) | First Affiliated Hospital of Guangxi Medical University, Genmedicn Biopharma Ltd. | Transfusion Dependent Beta-Thalassemia | 04/28 | 10/30 | | |
NCT05757245: A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants |
|
|
| Recruiting | 1 | 5 | RoW | GMCN-508A Drug Product | First Affiliated Hospital of Guangxi Medical University, Genmedicn Biopharma Ltd. | Transfusion-dependent α-Thalassemia | 08/28 | 12/30 | | |
| Enrolling by invitation | N/A | 3 | RoW | BRL-101, Autologous hematopoietic stem and progenitor cells injection | Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University | Sickle Cell Disease | 03/26 | 06/26 | | |
| Not yet recruiting | N/A | 45 | RoW | Assessments | Bioray Laboratories, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Shenzhen Children 's Hospital | Thalassemia, Beta | 08/38 | 10/38 | | |
NCT06685536: A Long-term Follow-up Study in Participants Who Received CS-101 |
|
|
| Enrolling by invitation | N/A | 5 | RoW | Safety and efficacy assessments | CorrectSequence Therapeutics Co., Ltd, First Affiliated Hospital of Guangxi Medical University | Beta-Thalassemia | 07/39 | 07/39 | | |
| Yu, Qitao |
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study |
|
|
| Not yet recruiting | 3 | 352 | RoW | olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen | Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy | 02/21 | 03/21 | | |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 404 | RoW | PM8002, Paclitaxel, Topotecan | Biotheus Inc. | SCLC | 01/27 | 12/28 | | |
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 71 | RoW | TQ-B3139 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/22 | 10/22 | | |
| Recruiting | 2 | 270 | RoW | TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | 10/25 | 02/26 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR |
|
|
| Recruiting | 1/2 | 160 | RoW | YK-029A | Suzhou Puhe Pharmaceutical Technology Co., LTD | Treatment, Treatment Side Effects | 12/23 | 05/24 | | |
NCT04284488: Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors |
|
|
| Recruiting | 1/2 | 104 | RoW | APG-1387 for Injection, Toripalimab, JS001 | Ascentage Pharma Group Inc. | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations |
|
|
| Recruiting | 1/2 | 290 | RoW | GFH375 | Genfleet Therapeutics (Shanghai) Inc. | KRAS G12D Mutations, Advanced Solid Tumors | 07/28 | 12/28 | | |
NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 220 | RoW | HSK40118 | Haisco Pharmaceutical Group Co., Ltd. | NSCLC | 08/25 | 06/27 | | |
